Jane Street Group LLC Sells 277,889 Shares of Assertio Holdings, Inc. (NASDAQ:ASRT)

Jane Street Group LLC lessened its holdings in Assertio Holdings, Inc. (NASDAQ:ASRT) by 68.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 128,684 shares of the company’s stock after selling 277,889 shares during the period. Jane Street Group LLC owned approximately 0.13% of Assertio worth $152,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of ASRT. Captrust Financial Advisors bought a new position in Assertio during the third quarter valued at $26,000. Point72 DIFC Ltd bought a new position in Assertio during the second quarter valued at $40,000. Thurston Springer Miller Herd & Titak Inc. increased its position in Assertio by 304.0% during the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 50,500 shares of the company’s stock valued at $60,000 after acquiring an additional 38,000 shares during the last quarter. Marshall Wace LLP bought a new position in Assertio during the second quarter valued at $70,000. Finally, Los Angeles Capital Management LLC bought a new position in Assertio during the second quarter valued at $77,000. Institutional investors own 48.96% of the company’s stock.

Assertio Stock Down 3.5 %

NASDAQ:ASRT opened at $0.81 on Tuesday. Assertio Holdings, Inc. has a 1-year low of $0.73 and a 1-year high of $1.80. The company has a 50-day moving average of $0.91 and a 200 day moving average of $1.14. The firm has a market cap of $77.04 million, a PE ratio of -1.11 and a beta of 0.78. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.01 and a quick ratio of 1.57.

Assertio (NASDAQ:ASRT) last released its quarterly earnings data on Monday, November 11th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. Assertio had a negative net margin of 54.46% and a positive return on equity of 3.79%. The company had revenue of $29.20 million during the quarter, compared to analyst estimates of $29.29 million. During the same period in the prior year, the firm earned ($0.01) earnings per share. As a group, research analysts anticipate that Assertio Holdings, Inc. will post -0.15 EPS for the current fiscal year.

Insider Buying and Selling at Assertio

In other Assertio news, Director Heather L. Mason bought 75,000 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were purchased at an average cost of $0.80 per share, for a total transaction of $60,000.00. Following the purchase, the director now directly owns 287,650 shares in the company, valued at $230,120. This represents a 35.27 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

ASRT has been the subject of a number of recent analyst reports. StockNews.com raised shares of Assertio from a “hold” rating to a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Assertio in a research note on Monday, December 16th.

Assertio Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.